Pfizer Revenue and Competitors
Estimated Revenue & Valuation
- Pfizer's estimated annual revenue is currently $69.3B per year.
- Pfizer's estimated revenue per employee is $646,165
- Pfizer's current valuation is $308.4B. (January 2022)
Employee Data
- Pfizer has 107310 Employees.
- Pfizer grew their employee count by 4% last year.
Pfizer's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Product Owner - Digital | Reveal Email/Phone |
2 | Service Now Product Owner | Reveal Email/Phone |
3 | Associate Director, Enterprise Knowledge Management & M365 Product Owner | Reveal Email/Phone |
4 | Trial Master File Study Owner | Reveal Email/Phone |
5 | TMF Study Owner / TMF Lead | Reveal Email/Phone |
6 | Product Owner, Senior Associate Lab the Future | Reveal Email/Phone |
7 | Company Owner | Reveal Email/Phone |
8 | Cloud Databases Product Owner | Reveal Email/Phone |
9 | Senior Manager Digital Product Owner COVID Franchise | Reveal Email/Phone |
10 | Service & Product Owner, IT Business Operations | Reveal Email/Phone |
Pfizer Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11830M | 8030 | 26% | $2.7B | $83B |
#2 | $32820M | 83449 | 7% | N/A | $182.4B |
#3 | $16.1M | 80 | 1% | N/A | N/A |
What Is Pfizer?
Pfizer Inc discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands. Our innovative, value-added products improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. The company has three business segments: health care, animal health and consumer health care. Our products are available in more than 150 countries.
keywords:Biotechnology
N/A
Total Funding
107310
Number of Employees
$69.3B
Revenue (est)
4%
Employee Growth %
$308.4B
Valuation
N/A
Accelerator
Pfizer News
Reports of two patients who found relief from long COVID after taking Pfizer Inc's antiviral Paxlovid, including a researcher who tested it...
Worldwide demand for Pfizer Inc's oral COVID-19 antiviral treatment Paxlovid has been unexpectedly light due to complicated eligibility...
Reports of two patients who found relief from long COVID after taking Pfizer Inc's antiviral Paxlovid, including a researcher who tested it...
Pfizer Announces Topline Results from Phase 2b Trial of Vupanorsen in Statin-treated Participants with Dyslipidemia Study met its primary endpoint, achieving a statistically significant reduction in non-high density lipoprotein cholesterol (non-HDL-C) - as well as a statistically significant r ...
NEW HAVEN, Conn. and NEW YORK, Nov. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commerc ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $39608.3M | 134722 | N/A | N/A |
#2 | $48393.9M | 157123 | 8% | N/A |
#3 | $131180M | 161444 | N/A | N/A |
#4 | $37345.1M | 190536 | N/A | N/A |
#5 | $74990M | 201882 | 5% | N/A |